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Summary 
The superantigen encoded by the mouse mammary 
tumor virus (MMTV) is a potent stimulator of T cells 
when bound to MHC class II molecules. Recent data 
from this laboratory have shown that the Mtv7 super- 
antigen, MIs-1, elicits a strong T cell response when 
presented by HLA-DR. To expand these observations 
further, we have produced the 28 kDa extracellular do- 
main and the 18 kDa carboxy-terminal subfragment of 
the MIs-1 protein in E. coil and studied their interaction 
with human MHC class II molecules in vitro. In this 
report, we demonstrate direct binding of these recom- 
binant forms of the MIs-1 protein to soluble HLA-DR1 
and HLA-DR4, but not to HLA-A2. Our data imply a 
unique class II interaction site of retroviral superanti- 
gens that is not shared with bacterial superantigens. 
Introduction 
Superantigens are a group of proteins that act as poly- 
clonal activators of T cells. This activation process takes 
place via the T cell receptor (TCR) VI3 chain and is depen- 
dent upon the interaction of the superantigen with MHC 
class II molecules. The association of the superantigen 
with the MHC class II protein occurs outside the peptide- 
binding groove (Dellabona et al., 1990; Karp et al., 1990) 
and is thought not to require processing (Carlsson et al., 
1988; Fleischer and Schrezenmeir, 1988). Although the 
interaction of a superantigen with the TCR is dependent 
on the expression of particular VI3 elements, evidence for 
the involvement of other TCR components in this process 
has recently been obtained (Smith et al., 1992; Vacchio 
et al., 1992; Quaratino et al., 1993; Woodland et al., 1993). 
Mouse mammary tumor viruses (MMTVs) exist as exog- 
enous infectious agents and as germline inherited ele- 
ments. The MMTV encodes a superantigen within the U3 
region of the 3' long terminal repeat (Acha et al., 1991; 
Choi et al., 1992). The expression of an endogenous su- 
perantigen is characterized by the deletion in vivo of imma- 
ture T cells expressing particular TCR V~ chains. Work 
from this laboratory has previously established that the 
endogenous virus Mtv7 encodes the superantigen known 
as MIs-1 (Beutner et al., 1992). In mice that are MIs-1 ÷, T 
cells expressing V~6, VI37, VI38.1, or V~9 chains are de- 
leted (Kappler et al., 1988; MacDonald et al., 1988). On 
the other hand, MIs-1 expressed on appropriate antigen- 
presenting cells elicits a strong proliferative response in 
vitro in T cells bearing TCR VI36 and V~8.1 (Happ et al., 
1989; Okada et al., 1990). 
A group of soluble bacterial toxins constitute the best- 
characterized collection of exogenous uperantigens (John- 
son et al., 1991). Direct binding of these proteins to MHC 
class II molecules has been demonstrated (Fischer et al., 
1989; Fraser, 1989; Mollick et al., 1989; Seth et al., 1994). 
Furthermore, binding domains and residues on both the 
toxin and the class II molecule have been identified (Her- 
man et al., 1991 ; Griggs et al., 1992; Karp and Long, 1992; 
Russell et al., 1992), and the crystal structure of a human 
class II molecule complexed with a bacterial superantigen 
has recently been published (Jardetzky et al., 1994). In 
contrast with the bacterial toxins with superantigen activ- 
ity, the MMTV superantigens are type II transmembrane 
glycoproteins whose interaction with MHC class II proteins 
has only been inferred so far from functional data. Our 
laboratory has shown that the human HLA-DR1 and HLA- 
DR4 proteins are capable of presenting MIs-1 to murine T 
cells (Subramanyam et al., 1993). In this study, we present 
evidence that recombinant subfragments derived from the 
extracellular domain of the MIs-1 protein directly bind to 
the MHC class II proteins HLA-DR1 and HLA-DR4, but 
not to the MHC class I molecule, HLA-A2. Our results indi- 
cate that a unique MHC class II binding site exists in the 
carboxy-terrninal fragment of the Mtv7 superantigen that 
is not shared with bacterial superantigens. 
Results and Discussion 
Production of Recombinant Mtv7 
Superantigen Fragments 
In an attempt o produce a soluble form of the Mtv7super- 
antigen, two fragments of this molecule were expressed 
in Escherichia coil; namely, the complete 28 kDa extracel- 
lular domain of the superantigen and the 18 kDa carboxy- 
terminal fragment have been produced, refered to as 
SAG28 and SAG18, respectively (Figure 1A). The frag- 
ment SAG18 was made to investigate the possibility that 
the superantigen is proteolyticalty processed to give rise 
to an 18 kDa biologically active form (Winslow et al., 1992, 
1994). Consistent with this hypothesis, the Mtv7superanti- 
gen contains a potential furin proteolytic cleavage site 
(Smeekens, 1993) at residues 168-171, which, if utilized, 
would result in an 18 kDa fragment. SAG18 and SAG28 
were expressed with amino-terminal polyhistidine tags to 
facilitate the purification of the proteins by N F + affinity chro- 
matography. Both superantigen fragments are insoluble 
when produced in E. coil and were, therefore, purified 
under denaturing conditions (Figure 1B). The identity of 
SAG 18 and SAG28 was confirmed with a monoclonal anti- 
body (MAb) generated against the carboxy-terrnina114 aa
of the Mtv7 superantigen (Mohan et al., 1993) (Figure 1C). 
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Figure 1. Structure and Purification of Recombinant Mis-1 
(A) Structure of the MMTV superantigen and recombinant superanti- 
gen derivatives. SAG18 and SAG28 are subfragments of the Mtv7 
superantigen produced in E. coli with NH2 terminal polyhistidine tags. 
TM, transmembrane region; RARR and RKRR are potential furin pro- 
teolytic leavage sites; his10, 10 residue polyhistidine tag; the cross- 
hatched region represents the COOH terminal epitope recognized by 
the anti-MIs-1 MAb 21C10. 
(B) Purification of SAG18 and SAG28. SDS-polyacrylamide gel of 
NF÷-nitrilotriacetate resin load an elutants. Lanes 1-5, SAG28 purifi- 
cation; lanes 6-10, SAG18 purification; lanes 1 and 6, resin loads; 
lanes 2 and 7, unbound material; lanes 3 and 8, insoluble material; 
lanes 4 and 9, resin wash; lanes 5 and 10, final elutants. SAG18 and 
SAG28 have an amino-terminal polyhistidine tag with an enterokinase 
cleavage site, which increases the molecular mass of the proteins by 
4 kDa. 
(C) Western blot of purified SAG 18 and SAG28. Lane 1, SAG28; lane 
2, SAG18. Molecular masses are given in kilodaltons. The blot was 
probed with the biotinylated anti-MIs-1 MAb 21C10, followed by strep- 
tavidin coupled to alkaline phosphatase. 
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After elution of the superantigen fragments from the NP-  
nitrilotriacetate resin, dialysis was carried out to remove 
the urea and facilitate refolding to produce a soluble prod- 
uct for structural analysis. While SAG28 could be pro- 
duced in such a soluble form at neutral pH, SAG18 was 
only soluble in 1 mM HCI. 
Binding of Soluble MHC Class II Molecules 
to Mtv7 Superantigen 
Superantigens are recognized by T cells in association 
with MHC class II molecules. Direct binding of the bacterial 
toxins to MHC class II proteins has been demonstrated 
(Fischer et al., 1989; Fraser, 1989; Mollick et al., 1989; 
Jardetzky et al., 1994; Seth et al., 1994), whereas binding 
of retrovirally encoded superantigens has only been in- 
ferred from functional data. To investigate whether MHC 
class II proteins are capable of binding to SAG18 and 
SAG28, both recombinant proteins were electrophoresed 
in an SDS-polyacrylamide gel, transferred to PVDF mem- 
brane, and probed with soluble forms of the MHC class 
II proteins HLA-DR1 and HLA-DR4 (Figure 2A). The results 
obtained indicate that the soluble form of HLA-DR is capa- 
ble of binding to SAG18 and SAG28. No nonspecific bind- 
ing of HLA-DR to MHC class I protein was observed (Figure 
2A). The decreased binding of the anti-HLA-DR antibody 
to the compact form of DR4 compared with DR1 can be 
explained by a reduced SDS stability of the DR4 sample 
used relative to the DR1 sample (data not shown). A small 
amount of nonspecific binding of the LB3.1 anti-DR MAb 
to purified SAG18 and SAG28 was observed (Figure 2A, 
lanes 5 and 6). To overcome this technical problem, we 
repeated the binding assay using iodinated MHC class II 
as probe (Figure 3A). With this assay system, the specific- 
ity of the binding reaction was established. 
To confirm further the specificity of the observed DR1 
and DR4 binding to SAG18 and SAG28, a soluble form 
of the MHC class I protein, HLA-A2, was used to probe 
similar blots of SAG18 and SAG28 (see Figure 213; Figure 
3B). In this case, no binding was observed, although con- 
trol binding to anti-HLA class I MAb was similar to that 
seen with class II molecules binding to anti-HLA class II 
MAbs. 
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Figure 2. Binding of Soluble HLA-DR1 and DR4, but not HLA-A2 to
SAG18 and SAG28 
The binding of soluble HLA-DR1 to SAG18 and SAG28 
is consistent with our previous demonstration that HLA-DR 
is capable of supporting a murine T cell response to the 
Mtv7superantigen (Subramanyam et al., 1993). HLA-DR1 
also presents the Mtv7 superantigen to human T cells, 
resulting in their proliferation (Labrecque et al., 1993). 
Concluding Remarks 
Recently, evidence has been presented for an overlapping 
binding site for staphylococcal enterotoxin A and the Mtvl 
superantigen on MHC class II molecules, using synthetic 
peptides derived from the Mtvl sag sequence (Torres et 
al., 1993). This site was localized to amino acid residues 
76-119 of the Mtvl superantigen, which is included in 
SAG28. However, our data demonstrate binding of MHC 
class II molecules to SAG18, a form of the superantigen 
missing residues 76-119. No detectable difference in 
binding of HLA-DR1 or HLA-DR4 to SAG18 and SAG28 
was observed (see Figure 2A). Taken together, both our 
data and that of Torres et al. (1993) suggest two binding 
sites on the MMTV superantigen for MHC class II proteins. 
The first site, located close to the transmembrane domain, 
binds to the same MHC class II residues as staphylococcal 
enterotoxin A, and the second more carboxy-terminal site 
is unique to the MMTV superantigen. From our results, 
we conclude that the carboxy-terminal 18 kDa fragment 
of the Mtv7 su perantigen contains all the necessary struc- 
tural attributes for association with the MHC class II pro- 
tein, a result that supports the hypothesis that SAG18 is 
the biologically active form of the MMTV superantigen 
(Winslow et al., 1992, 1994). It has been shown that a 
number of residues in the MHC class II protein that are 
critical for the binding of bacterial superantigens (including 
staphylococcal enterotoxin A) are not essential for the pre- 
sentation of superantigens encoded by Mtv7 and Mtv9 
(Thibodeau et al., 1994). These results are also consistent 
with a two-site model for MMTV superantigen binding to 
MHC class II proteins. 
The presented data indicate that processing of the Mtv7 
superantigen through the conventional antigen presenta- 
tion pathway is not necessary for association with MHC 
class II molecules, in accordance with what has been dem- 
onstrated for the bacterial superantigens (Carlsson et al., 
(A) Lanes 1, 4, 8, 12, papain-solubilized HLA-A2; lanes 2, 5, 9, 13, 
SAG18; lanes 3, 6, 10, 14, SAG28; lanes 7 and 11, papain solubilized 
HLA-DR1; lane 15, papain solubilized HLA-DR4. The samples con- 
taining soluble DR1 and DR4 were not boiled before electrophoresis 
and thus migrate as the compact form. Lane 1 was probed with anti- 
class I rabbit antiserum, followed by alkaline phosphatase-coupled 
goat anti-rabbit immunoglobulin; lanes 2 and 3 were probed with biotin- 
ylated anti-MIs-1 MAb 21C10; lanes 4-7 with a biotinylated anti-HLA- 
DR MAb (LB3.1); lanes 8-11 were probed initially with soluble HLA- 
DR1, followed by biotinylated LB3.1 ; lanes 12-15 were probed initially 
with soluble HLA-DR4, followed by biotinylated LB3.1. Alkaline phos- 
phatase-coupled streptavidin was used for all blots probed with biotin- 
ylated MAbs. Molecular masses are given in kilodaltons. 
(B) Probing of SAG18 and SAG28 with soluble HLA-A2. Lane 1 
(SAG28) and lane 2 (SAG 18) were probed initially with soluble H LA-A2, 
followed by anti-M HC class I MAb, PA2.1, and goat anti-mouse alkaline 
phosphatase-coupled Ab. Molecular masses are given in kilodaltons. 
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Figure 3. Probing of SAG18 and SAG28 with Iodinate HLA Proteins 
(A) Probing with iodinated HLA-DR1 protein: SAG18 (lane 2) and SAG28 (lane 1) were run on an SDS-polyacrylamide g l, transferred to PVDF 
membrane, and probed with 12~l-labeled HLA-DR1. Bottom: Serially diluted anti-HLA-DR MAb, LB3.1, was blotted onto the nylon membrane and 
probed with the iodinated HLA-DR1 (positive control). 
(B) Probing with iodinated HLA-A2 protein: aduplicate blot of (A) was probed with ~2~l-labeled HLA-A2. Bottom: Serially diluted anti-HLA-A2 MAb, 
PA2.1, was blotted onto the nylon membrane and probed with iodinated HLA-A2 (positive control). 
1988; Fleischer and Schrezenmeir, 1988). These results 
raise the questions as to where the superantigen and the 
MHC class II protein associate in vivo, and whether proteo- 
lytic cleavage of the superantigen is necessary for biologi- 
cal activity. We are currently investigating these points in 
in vivo MIs-1 expression experiments, by transfecting the 
Mtv7 sag gene into mutant cell ines that are unable to 
process MHC class II-associated peptides (Mellins et al., 
1994; Morris et al., 1994) and by testing specific inhibitors 
of the furin protease. Further, the binding assays we have 
developed for detecting the interaction of the Mtv7 super- 
antigen with MHC class II molecules will allow us to map 
the critical residues within the superantigen ecessary for 
the binding of the MHC class II protein. These studies are 
part of our larger goal, to understand the MMTV superanti- 
gen-MHC class II-TCR interaction at the molecular level. 
We have already carried out preliminary binding studies 
of recombinant TCR V[36 protein to SAG18 and SAG28, 
using the BIAcore, and we have determined that this inter- 
action is 50- to 100-fold higher affinity than the MHC class 
II interaction with the recombinant superantigen (P.-N. H. 
and B. T. H., unpublished data), in agreement with what 
has been reported recently for bacterial superantigens 
(Seth et al., 1994). It is possible, therefore, that the TCR 
stabilizes the interaction of the superantigen to MHC class 
II proteins, either by introducing a conformational change 
in the superantigen, or by forming a trimolecular complex 
that stabilizes the class II-superantigen interaction. 
The presented results suggest that MIs-1 does not bind 
to the outer loops of the DR~ chain, because the class II 
molecule can still be recognized by the MAb LB3.1, whose 
binding sites have been accurately mapped on the DR~ 
chain (Fu and Karr, 1994). From these results, we can 
conclude that MIs binds mainly to the DR~ chain, as we 
have suggested previously from our functional data (Su- 
bramanyam et al., 1993). 
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Experimental Procedures 
Materials 
HLA-DR molecules were purified from homozygous Epstein-Barr vi- 
rus-transformed human B lymphocyte lines, DR-1 from LG-2 (HLA- 
DRA, DRBI*01Ol), and DR4 from Priess (HLA-DRA, DRBI*0401) 
cells, and solubilized by limited papain digestion as described (Gorga 
et al., 1987, 1991). Water-soluble HLA-A2 was produced by limited 
papain digestion as previously described (Gorga et al., 1992). The 
anti-HLA-DR MAb LB3.1 (immunoglobulin G2b) was purified via pro- 
tein A chromatography (MACTM, Amicon, Massachusetts) and bio- 
tinylated using NHS-LC-biotin, as described by the manufacturer 
(Pierce, Rockford, Illinois). The anti-HLA-class I MAb PA2.1 (IgG1) 
was obtained from American Type Culture Collection (Parham and 
Bodmer, 1978). The murine anti-MIs-1 MAb-secreting hybridoma 
21C 10 was generated as previously described for the hybridom a 3B 12 
(Mohan et al., 1993). 
Construction of pET-19SAG18 and pET-19SAG28 
The plasmids pET-19SAG18 and pET-19SAG28 were constructed by 
polymerase chain reaction cloning the Mtv7 sag gene subfragments 
encoding the proteins SAG 18 and SAG28 (see Figure 1A) from a geno- 
rnic clone (Beutner et al., 1992) into the BamHI site of pET-19b (Nova- 
gen, Incorporated, Madison, Wisconsin), using the following primers: 
SAG18, 5' primer GGGGATCCAATGCGCTCAACCGCAGTC, 3' primer 
GGGCTAGCGGATCCGCAAGTAGACCTG; and SAG28, 5' primer 
GGGGATCCTGGGGAAGTTGCGGTT, and 3' primer as for SAG18. 
The correct orientation of the fragment was confirmed by restriction 
endonuclease digestion. 
Production and Purification of SAG18 and SAG28 
The proteins SAG18 and SAG28 were produced by IPTG induction 
of the plasmids pET-19SAG18 and pET-19SAG28 in E. coil strain 
BL21(DE3). Cells from an overnight inoculum were grown on a shaker 
at 37°C until they reached a density with an A600 of 0.6-0.9, then 
induced by adding IPTG to a concentration of 1 mM and left shaking 
overnight at 37°C. Cells were pelleted at 2,500 x g for 15 min and 
frozen at -70°C. The induced cell pellets from 500 rnl of cell culture 
were thawed at room temperature, resuspended in 50 ml buffer A (8 
M urea, 100 mM Tris-HCI [pH 8.0]), and homogenized in a dounce. 
Cells were lysed by continual mixing at room temperature for 1 hr 
(all subsequent manipulations were carried out at room temperature). 
Insoluble material was removed by centrifugation at 10,000 x g for 
15 min. The supernatant was mixed for 1 hr with 1 ml of packed NF ÷- 
nitrilotriacetate resin (Qiagen, Incorporated, Chatsworth, California) 
equilibrated with buffer A. The resin was pelleted at 800 x g for 30 
s and washed twice in buffer A (10 ml buffer A per ml of resin). The 
resin was further washed twice with buffer B (8 M urea, 1 M NaCI, 20 
mM imidazole [Sigma Chemical Company, St. Louis, Missouri], 100 
rnM TrIs-HCI, [pH 6.3]). Final elution of SAG18 and SAG28 was per- 
formed by resuspending the resin in 7 ml of buffer C (8 M urea, 0.5 
M imidazole, 100 mM Tris-HCI [pH 8.0]) and mixing for 15 rain. The 
eluted protein was stored at-70°C. Protein concentrations were deter- 
mined by bicinchoninic acid assay (Pierce, Rockford, Illinois). 
SDS-PAGE and Western Blotting 
Protein samples were diluted in SDS-PAGE sample buffer with 2-ME 
(5%) and boiled for 5 rain (unless otherwise stated) before electropho- 
resis on 12% SDS-polyacrylamide gels. Western blotting was carried 
out as previously described (Towbin et al., 1979) after electrotransfer 
to PVDF membrane (Millipore Corporation, Bedford, Massachusetts). 
Probing of SAG18 and SAG28 with soluble forms of the MHC proteins 
(HLA-DR1, HLA-DR4, and HLA-A2) was carried out by incubating the 
PVDF membrane, which was previously blocked with 5% milk powder, 
with the soluble.MHCprotein in PBS, 0.2% Tween 20 at 10 I~g/ml for 
1 hr at room temperature. Detection of HLA-DR1 or HLA-DR4 was 
with a biotinylated MAb specific for H LA-DR (LB3.1), followed by strep- 
tavidin-conjugated alkaline phosphatase (Bio-Rad Laboratories, Incor- 
porated, Richmond, California). HLA-A2 was detected using a mouse 
MAb, PA2.1, specific for HLA-A2, followed by alkaline phosphatase- 
conjugated goat anti-mouse immunoglobulin (Bio-Rad Laboratories, 
Incorporated, Richmond, California). 
Iodination of MHC molecules was performed by using the Iodo- 
beads iodination reagent (Pierce, Rockford, Illinois). Soluble MHC mol- 
ecules (200 p.g) were iodinated with 0.5 mCi Na 12Sl in the reaction 
with the beads, Iodinated samples were purified by gel filtration to 
remove the unincorporated 1251 from the iodinated protein. The binding 
specificity was determined on a nylon membrane containing serially 
diluted anti-HLA-DR and anti-HLA class I MAbs. Binding to the Western 
blot was performed by incubating the PVDF membrane, which was 
blocked with 5% milk powder, with the soluble iodinated MHC protein 
in PBS, 0.2% Tween 20 for 1 hr at room temperature. 
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